Exhaled Breath Analysis in Lymphangioleiomyomatosis by Real-Time Proton Mass Spectrometry
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26136005 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Malika Mustafina und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Functional and Ultrasound Diagnostics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Mo…. Hauptthemen laut MEDLINE: Lymphangioleiomyomatosis, Volatile Organic Compounds, Mass Spectrometry. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, the Ministry of Science and Higher Education of the Russian Federation within the framework of state support for the creation and development of World-Class Re…, the government assignment "Application of mass spectrometry and exhaled air emission spectrometry for cardiovascular risk stratification".
Abstract (Originalsprache)
Lymphangioleiomyomatosis (LAM) is a rare progressive disease that affects women of reproductive age and is characterized by cystic lung destruction, airflow obstruction, and lymphatic dysfunction. Current diagnostic methods are costly or lack sufficient specificity, highlighting the need for novel non-invasive approaches. Exhaled breath analysis using real-time proton mass spectrometry (PTR-MS) presents a promising strategy for identifying disease-specific volatile organic compounds (VOCs). This cross-sectional study analyzed exhaled breath samples from 51 LAM patients and 51 age- and sex-matched healthy controls. PTR-time-of-flight mass spectrometry (PTR-TOF-MS) was employed to identify VOC signatures associated with LAM. Data preprocessing, feature selection, and statistical analyses were performed using machine learning models, including gradient boosting classifiers (XGBoost), to identify predictive biomarkers of LAM and its complications. We identified several VOCs as potential biomarkers of LAM, including m/z = 90.06 (lactic acid) and m/z = 113.13. VOCs predictive of disease complications included m/z = 49.00 (methanethiol), m/z = 48.04 (O-methylhydroxylamine), and m/z = 129.07, which correlated with pneumothorax, obstructive ventilation disorders, and radiological findings of lung cysts and bronchial narrowing. The classifier incorporating these biomarkers demonstrated high diagnostic accuracy (AUC = 0.922). This study provides the first evidence that exhaled breath VOC profiling can serve as a non-invasive additional tool for diagnosing LAM and predicting its complications. These findings warrant further validation in larger cohorts to refine biomarker specificity and explore their clinical applications in disease monitoring and personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Functional and Ultrasound Diagnostics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.
- Pulmonology Research Institute under the Federal Medical and Biological Agency of Russia, 115682 Moscow, Russia.
- Research Institute for Systemic Analysis of the Russian Academy of Sciences, 117218 Moscow, Russia.
- World-Class Research Center "Digital Biodesign and Personalized Healthcare", I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.
- N.I. Pirogov Russian National Research Medical University, 1 Ostrovityanova str., Bldg. 6, 117513 Moscow, Russia.
- National Medical Research Center of Otorhinolaryngology, Federal Medical and Biological Agency of Russia, 123182 Moscow, Russia.
ORCID-Profile: Malika Mustafina, Marina Makarova, Aleksandr Suvorov, Alexander Chernyak, Pavel Pakhomov, Ekaterina Pershina, Olga Suvorova, Anna Shmidt, Anastasia Gordeeva, Olesya Bahankova, Aleksandra Bykova
Förderung
- Russian Science Foundation
- the Ministry of Science and Higher Education of the Russian Federation within the framework of state support for the creation and development of World-Class Re…
- the government assignment "Application of mass spectrometry and exhaled air emission spectrometry for cardiovascular risk stratification"
- RSF
- the government assignment
Zitieren
APA
Mustafina, M., Silantyev, A., Makarova, M., Suvorov, A., Chernyak, A., Naumenko, Z., Pakhomov, P., Pershina, E., Suvorova, O., Shmidt, A., Gordeeva, A., Vergun, M., Bahankova, O., Gognieva, D., Bykova, A., Belevskiy, A., Avdeev, S., Betelin, V., & Kopylov, P. (2025). Exhaled Breath Analysis in Lymphangioleiomyomatosis by Real-Time Proton Mass Spectrometry. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136005
Vancouver
Mustafina M, Silantyev A, Makarova M, Suvorov A, Chernyak A, Naumenko Z, et al. Exhaled Breath Analysis in Lymphangioleiomyomatosis by Real-Time Proton Mass Spectrometry. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136005
BibTeX
@article{Mustafina2025,
author = {Mustafina, Malika and Silantyev, Artemiy and Makarova, Marina and Suvorov, Aleksandr and Chernyak, Alexander and Naumenko, Zhanna and Pakhomov, Pavel and Pershina, Ekaterina and Suvorova, Olga and Shmidt, Anna and Gordeeva, Anastasia and Vergun, Maria and Bahankova, Olesya and Gognieva, Daria and Bykova, Aleksandra and Belevskiy, Andrey and Avdeev, Sergey and Betelin, Vladimir and Kopylov, Philipp},
title = {Exhaled Breath Analysis in Lymphangioleiomyomatosis by Real-Time Proton Mass Spectrometry},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26136005}
}
EUVIMED